A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
iOnctura
Merck Sharp & Dohme LLC
Pfizer
RemeGen Co., Ltd.
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
AstraZeneca
Cullinan Therapeutics Inc.
National Cancer Institute (NCI)
Tesaro, Inc.
Amgen
Memorial Sloan Kettering Cancer Center
MedImmune LLC